Halia Therapeutics
Halia Therapeutics, Inc.
Learn how Halia Therapeutics pioneers groundbreaking therapies address genetic resilience in families targeting NLRP3 and inflammation-related chronic disease.
haliatx.com · Lehi, UT
Funding event
The round itself, as filedInferred stageSeed
Sold of offered$3.5M of $20.0M
Filed2026-08-31
Days since filing33
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-08-17
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Jeffrey BurtonExecutive Officer
- David BearssDirector
- David CheckettsDirector
- John S.K. KauweDirector
- Gary B. SabinDirector
- Mary BeckerleDirector
- Preston CampbellDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged17.4% sold1.5 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-210
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.